Laurence Zitvogel Selected Research

Calreticulin

12/2021	Subversion of calreticulin exposure as a strategy of immune escape.
1/2019	Contribution of annexin A1 to anticancer immunosurveillance.
1/2019	Anticancer effects of anti-CD47 immunotherapy in vivo.
1/2019	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers.
1/2018	eIF2α phosphorylation is pathognomonic for immunogenic cell death.
7/2016	Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer.
1/2014	Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress.
8/2013	Potent immunomodulatory effects of the trifunctional antibody catumaxomab.
9/2012	An immunosurveillance mechanism controls cancer cell ploidy.
6/2010	Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laurence Zitvogel Research Topics

Disease

319	Neoplasms (Cancer) 07/2022 - 07/2002
44	Melanoma (Melanoma, Malignant) 01/2022 - 07/2002
25	Breast Neoplasms (Breast Cancer) 01/2020 - 09/2007
17	Neoplasm Metastasis (Metastasis) 01/2021 - 03/2004
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 05/2012
11	Carcinogenesis 01/2022 - 03/2012
9	COVID-19 01/2022 - 01/2020
9	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 05/2012
9	Carcinoma (Carcinomatosis) 01/2018 - 09/2012
9	Necrosis 01/2017 - 04/2009
8	Inflammation (Inflammations) 01/2022 - 05/2004
8	Lung Neoplasms (Lung Cancer) 01/2020 - 08/2012
7	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2017 - 08/2004
7	Residual Neoplasm 01/2014 - 10/2002
5	Infections 01/2022 - 10/2005
4	Disease Progression 01/2020 - 05/2012
3	Dysbiosis 01/2022 - 01/2016
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 10/2012
3	Colonic Neoplasms (Colon Cancer) 01/2021 - 11/2008
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 06/2015
3	Cadaver (Cadavers) 01/2019 - 06/2010

Drug/Important Bio-Agent (IBA)

47	AntigensIBA 01/2022 - 07/2002
37	AnthracyclinesIBA 01/2021 - 03/2007
29	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 12/2007
28	CytokinesIBA 01/2022 - 05/2004
28	VaccinesIBA 01/2022 - 02/2006
24	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
21	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2004
21	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 06/2006
21	CalreticulinIBA 12/2021 - 01/2007
19	Peptides (Polypeptides)IBA 01/2022 - 09/2003
19	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2007
18	LigandsIBA 01/2021 - 12/2006
16	InterferonsIBA 10/2021 - 02/2006
16	Pharmaceutical PreparationsIBA 07/2020 - 02/2010
16	HMGB1 Protein (HMG1)IBA 06/2016 - 09/2007
15	Monoclonal AntibodiesIBA 10/2019 - 08/2008
14	Adenosine Triphosphate (ATP)IBA 01/2019 - 10/2009
13	Biological ProductsIBA 10/2021 - 01/2003
13	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 03/2006
11	Therapeutic UsesIBA 10/2020 - 12/2007
11	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2006
10	InterleukinsIBA 01/2020 - 03/2010
10	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 08/2004
9	AntibodiesIBA 12/2021 - 03/2004
9	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 11/2013
9	Toll-Like Receptor AgonistsIBA 01/2018 - 10/2008
8	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 06/2006
8	CarcinogensIBA 01/2021 - 07/2011
8	Toll-Like Receptor 4IBA 02/2016 - 09/2007
8	Neoplasm Antigens (Tumor Antigens)IBA 04/2013 - 02/2006
7	Pattern Recognition ReceptorsIBA 01/2021 - 08/2009
7	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020 - 09/2008
7	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2019 - 03/2013
6	Interleukin-2 (IL2)IBA 01/2020 - 10/2002
6	ChemokinesIBA 01/2018 - 06/2008
6	Protein Isoforms (Isoforms)IBA 01/2016 - 08/2004
5	Hormones (Hormone)IBA 01/2022 - 10/2012
5	Immunologic Adjuvants (Immunologic Adjuvant)IBA 02/2016 - 09/2007
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014 - 12/2005
5	Cytotoxins (Cytolysins)IBA 01/2014 - 12/2006
5	Interferon-gamma (Interferon, gamma)IBA 02/2010 - 12/2006
4	Tyrosine Kinase InhibitorsIBA 07/2022 - 06/2011
4	EpitopesIBA 01/2022 - 03/2005
4	Histocompatibility Antigens Class IIBA 01/2019 - 04/2013
4	Chemokine ReceptorsIBA 01/2018 - 09/2015
4	Immunomodulating AgentsIBA 11/2016 - 07/2012
4	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2016 - 03/2011
4	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 06/2016 - 01/2015
4	EnzymesIBA 05/2015 - 12/2011
4	IpilimumabIBA 02/2015 - 11/2012
4	Interleukin-18 (Interleukin 18)IBA 11/2014 - 08/2011
4	Cancer VaccinesIBA 01/2014 - 02/2006
4	Imiquimod (Aldara)FDA LinkGeneric 01/2014 - 08/2012
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2013 - 05/2004
4	HLA-A2 Antigen (HLA A2 Antigen)IBA 03/2005 - 09/2003
3	Immunologic Factors (Immunomodulators)IBA 07/2022 - 01/2016
3	Blocking AntibodiesIBA 01/2022 - 09/2013
3	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2019
3	Immunoglobulin G (IgG)IBA 12/2021 - 12/2012
3	RNA (Ribonucleic Acid)IBA 12/2021 - 01/2020
3	Annexin A1IBA 01/2021 - 01/2019
3	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2021 - 11/2015
3	SpermidineIBA 01/2021 - 11/2016
3	Poly A-UIBA 01/2020 - 01/2010
3	CrizotinibIBA 01/2020 - 01/2019
3	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2020 - 03/2011
3	Interferon Type IIBA 01/2020 - 11/2014
3	Messenger RNA (mRNA)IBA 01/2018 - 01/2017
3	Natural Cytotoxicity Triggering Receptor 1IBA 01/2018 - 01/2015
3	VemurafenibIBA 01/2017 - 01/2014
3	Natural Killer Cell ReceptorsIBA 01/2017 - 06/2011

Therapy/Procedure

123	Therapeutics 07/2022 - 03/2005
84	Immunotherapy 07/2022 - 08/2002
73	Drug Therapy (Chemotherapy) 01/2022 - 12/2005
21	Radiotherapy 01/2020 - 12/2006
6	Adjuvant Chemotherapy 06/2016 - 05/2012
5	Neoadjuvant Therapy 01/2020 - 01/2014
4	Oncolytic Virotherapy 01/2017 - 06/2013
3	Transplantation 10/2021 - 08/2011